Purpose: Antiepileptic drugs (AEDs), particularly valproate (VPA), are known to be teratogens when taken by women with epilepsy (WWE), but the risk in women who take these drugs for indications other than epilepsy have been little studied. This study aims to investigate the incidence of birth defects in children born to mothers taking AEDs for non-epilepsy indications. Methods: The Australian Pregnancy Register (APR), established in 1998, is a prospective observational study operating with ethical approval and informed written consent for participation. Of the 2066 pregnancies enrolled in the Register, 98% are WWE and the remainder received AEDs for other indications. Data from this Register was analysed to study the rates of congenital malformations (CM) in infants exposed to AEDs in utero in WWE compared to those women taking AEDs for other indications. Results: The malformation rates in pregnancies of WWE taking AEDs (5%), is higher than the rates of infants born to untreated WWE (2%). There were 32 pregnancies enrolled from 29 mothers taking AEDs for indications other than epilepsy (2 women/2 pregnancies were lost to follow up). Out of 30 pregnancies, 9 of which were exposed to VPA, 1 resulted in a child with a malformation (3%) (cleft palate) on 1700 mg/day of valproate. Conclusions: This is the first attempt to assess the use of AEDs in a prospective study of women who are pregnant but do not have active epilepsy. Although underpowered, this study suggests that women taking AEDs for non-epilepsy indications have a similar risk of having a child with a CM as compared with women taking AEDs for epilepsy. Larger numbers are required to investigate the risk of AED-associated malformations in this important group.
Introduction
Antiepileptic drugs (AEDs) have been used to treat indications other than epilepsy for over 50 years, but this usage has increased over recent years [1] . Non-epileptic conditions include both mood disorders and neurological conditions. The following are the main non-epilepsy indications treated by AEDs and the drugs used to treat them (drugs used to treat are in parenthesis, for abbreviations see below*): bipolar disorder (VPA, CBZ, LTG), anxiety (VPA, LTG, TPM, benzodiazepines), migraine (VPA, TPM), neuropathic pain (VPA, CBZ, TPM, PHT), trigeminal neuralgia (VPA, LTG, TPM), schizophrenia (VPA, CBZ, LTG) and multiple sclerosis (CBZ, LTG, GBP). AEDs have been particularly effective in treating bipolar disorder, and some AEDs such as VPA and LTG are now first line treatments [2, 3] . Bipolar disorder typically manifests during reproductive years [4] , and pregnant women with bipolar disorder who are not medicated have an increased risk of a recurrence of symptoms as well unfavorable pregnancy outcomes, making it difficult for women to safely cease the drug [5] . Similarly, women are 2-3 times more likely to develop multiple sclerosis (MS) than men and over 50% of patients with MS develop their symptoms during their childbearing years [6] .
Exposure to AEDs during the first trimester of pregnancy in women with epilepsy is established for most AEDs to increase the risk threefold of having a child with a birth defect. This risk is increased up to 17-fold for VPA [7] [8] [9] . However, whether AED teratogenicity is specific to patients with epilepsy, or whether it affects all indications has not yet been well studied. This paper reports the incidence of birth defects for a cohort of women taking 
The Australian pregnancy register
The Australian Pregnancy Register (APR) is a national, prospective, observational, telephone interview-based register recruiting three groups of women:
1. WWE taking AEDs during the first trimester of pregnancy 2. WWE not taking AEDs during the first trimester of pregnancy 3. Women without epilepsy taking AEDs during the first trimester of pregnancy Details of the register have been reported elsewhere [10] . Women were recruited nationwide on a voluntary basis. Eligible women were made aware of the Register through their medical practitioners, health professionals and other relevant sources such as the website and social media. All communication with women was on the telephone. Four interviews were conducted: in the first or second trimester of pregnancy, at 7 months of pregnancy, within the first month of birth and at the end of the first or second year. Details of the pregnancy and birth such as birth defects were recorded into the confidential database and each mother was given an individual identification number.
Data analysis
All data for this analysis was collected from the APR between mid-1999 and August 2016. Relevant data was found by filtering the database for case subjects without epilepsy and AED exposed controls without epilepsy. Details of each subject's AEDs and birth outcomes were recorded and assessed for any birth defects. Statistical analysis was not conducted due to the small numbers but comparisons were made between the different groups defined above. Ethical approval was obtained from The Melbourne Health Human Research Ethics Committee (HREC).
Results
At the time of this analysis there were 2066 pregnancies enrolled in the APR, including 38 twin pregnancies. Of these pregnancies, 32 were from women taking AEDs for a non-epilepsy indication, 2 of which were lost to follow up. 27/30 pregnancies were from unique women, while 3 women had 2 pregnancies each. For 17/30 pregnancies the women were taking folate before conception. All but three pregnancies involved folate supplementation in the first trimester. The indications as listed in Table 1 are: bipolar disorder (n = 16), pain (n = 6), multiple sclerosis (n = 2) anxiety (n = 1), depression (n = 1), hyperekplexia (n = 2), periodic ataxia (n = 1) and sleep disorder (n = 1). Of these 30 pregnancies, 1 resulted in a child with a major congenital malformation (cleft palate) in 2002. The mother of this child was taking VPA 1700 mg for bipolar disorder. She was taking folate before conception and also in the first trimester at a dose of 1 mg. Her pregnancy was registered in the Australian Pregnancy Register before the child with the malformation had been born. She had one induced abortion (maternal choice) earlier in 1993 while not on AEDs, prior to her VPA exposed pregnancy. Table 1 shows the total number of non-epileptic women in the Australian Pregnancy Register suffering from each non-epileptic indication followed by which AED was taken during pregnancy. There were 32 women taking AEDs for indications other than epilepsy however 2/32 were lost to follow up and are therefore not included. Two of the women with bipolar disorder were on AED polytherapy, both of which included VPA in the combination. Hyperekplexia: a neurological condition in which sufferers experience exaggerated reactions to noise, movement or touch. Table 2 shows the dose ranges of VPA. All patients suffered a bipolar disorder. The most common doses were above 300 mg and up to 2000 mg which is above the upper limit of permissible doses for pregnant WWE [7, 9, 11] . Table 3 shows the number of birth defects in all categories of women enrolled in the Australian Pregnancy Register. Those lost to follow up have been excluded (20 pregnancies in total). It should be noted that of the 94 pregnancies resulting in a defect in WWE taking AEDs in the first trimester 5 were twin pregnancies. 2/5 twin pregnancies resulted in both twins having defects while in 3/5 only one of the twins had a defect. There were no twin pregnancies with defects in the other patient groups. 
Discussion
Fetal exposure to AEDs has been reported to be associated with a multitude of anatomical congenital malformations and cognitive deficits. These malformations were first reported by Holmes et al. (2001) [12] to be caused by exposure of the fetus to AEDs and not due the mother's seizures. Data from previous studies shows conclusively that VPA is the most significant teratogen compared to traditional and second generation AEDs currently available, and that other AEDs pose a less potent teratogenic risk [7, 8] Although this study was underpowered, because of the small number of pregnant women taking AEDs for a non-epilepsy indication, the data suggests that these women have a similar risk of having an infant with a congenital malformation (3%) as WWE taking AEDs (5%). Our study is underpowered partly because of low total denominators but also because of different medication combinations and doses, however this kind of study can potentially deliver relevant results. The incidence of malformations in both the AED-treated groups was slightly higher than that in WWE who were not taking an AED for their entire pregnancy (2%).
The mother of the single child with a congenital malformation who was taking VPA during her pregnancy, was also taking antidepressant sertraline concurrently. In this family consisting of mother, father and one child, the mother has a bipolar disorder and had a previous spontaneous abortion while she was on no medication. Subsequently she had a child with a cleft palate while taking VPA 1700 mg per day. We cannot ignore that the past history of this woman may be a complicating factor as she had epilepsy in childhood which resolved by the age of 14, however this cannot be regarded as active epilepsy. This analysis focused on the indication each woman was taking AEDs for at the time of pregnancy and this case was therefore considered for her bipolar disorder. In order to allay fears of reporting bias it is important to note that the pregnancy was enrolled in the register before the child was born. The mother had been taking folate both before conception and in the first trimester. In this cohort, only 17/30 pregnancies involved folate supplementation before conception and 27/30 in the first trimester. Neurologists are more likely to prescribe folate to women with epilepsy than women taking AEDs for non-epilepsy indications [13] , another reason it is critical this patient group is addressed.
Our results, reporting on a single birth defect in a child exposed to high dose VPA during pregnancy for a psychiatric indication, is in accord with the published literature that highlights the risk associated with high dose VPA in WWE. One out of the nine children exposed to VPA during pregnancy one had a defect, which is higher than one would expect by chance. In Australia, the prevalence of oral facial clefts ranges from between 15 and 21 per 1000 births [14] , again a smaller percentage than what we observed. The small numbers in this study may be due to underreporting. In Australia, the use of VPA for non-epilepsy indications is increasing. One of our earlier papers shows the increase of AEDs for psychiatric conditions compared with non-epilepsy indications, but it is not numerically defined [15] . A study in the United States found that more women of child bearing age were prescribed VPA for nonepileptic indications than for epilepsy [16] . Although precise numerical data is not available for the Australian population, this highlights the importance and potential underreporting of this patient group. Although there is limited published data regarding outcomes in this group one study found increased spontaneous abortions in women taking AEDs for non-epilepsy indications compared with WWE taking AEDs [17] . This may be another factor to assess in future analysis. Another possible route to take in future analysis would be to follow these children developmentally and assess for developmental disabilities aside from congenital malformations.
Conclusion
The question of the teratogenic risk of AEDs prescribed to women for indications other than epilepsy, has not been studied prospectively previously. This is an important issue given the increasing prescription of this class of drugs for non-epileptic indications. The interaction of epilepsy or the genetic background predisposing to epilepsy could influence the rate of malformations in women taking AEDs. Therefore, studies that specifically address this question are urgently required. However, the experience of the APR and other AED pregnancy registers is that this patient group is more difficult to enrol. The question does arise as to whether there is an underreporting of pregnancies in women with indications other than epilepsy. Our study, although underpowered, is the first study to specifically investigate this important question. The data suggest that exposure to a high dose of VPA during the first trimester of pregnancy in women taking AEDs for a non-epilepsy indication may pose a similar risk to that reported in WWE. Further research with larger numbers are required confirm this. This study may be viewed as a preliminary report which needs to be validated by one of the international pregnancy registers. It provides a platform and motivation upon which further research can take place.
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